Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
Tubulis has appointed Matthew Norkunas, MD, MBA, as Chief Financial Officer and President of Tubulis Inc. Based in the company's Cambridge office, this appointment strengthens their U.S. presence and executive leadership. Dr. Norkunas brings significant experience in biotech financial leadership, having previously served as CFO at Generation Bio (GBIO) and SomaLogic.
His background combines medical expertise as a trained anesthesiologist with extensive financial acumen, including experience in healthcare investment and operational roles. The appointment comes at a important growth stage for Tubulis, which is developing ADC (Antibody-Drug Conjugate) drug candidates. Dr. Norkunas will focus on advancing the company's strategic objectives and positioning it for long-term success in the ADC space.
Tubulis ha nominato Matthew Norkunas, MD, MBA come Chief Financial Officer e Presidente di Tubulis Inc. Con sede nell'ufficio di Cambridge della società, questa nomina rafforza la loro presenza negli Stati Uniti e la leadership esecutiva. Il Dott. Norkunas porta con sé una significativa esperienza nella leadership finanziaria nel settore biotech, avendo precedentemente ricoperto il ruolo di CFO presso Generation Bio (GBIO) e SomaLogic.
Il suo background unisce competenze mediche come anestesiologo addestrato a una vasta conoscenza finanziaria, inclusa esperienza in investimenti sanitari e ruoli operativi. La nomina avviene in una fase di importante crescita per Tubulis, che sta sviluppando candidati farmaceutici ADC (Antibody-Drug Conjugate). Il Dott. Norkunas si concentrerà sul progresso degli obiettivi strategici dell'azienda e sul posizionamento per un successo a lungo termine nel settore ADC.
Tubulis ha nombrado a Matthew Norkunas, MD, MBA como Director Financiero y Presidente de Tubulis Inc. Con sede en la oficina de la empresa en Cambridge, este nombramiento refuerza su presencia en Estados Unidos y el liderazgo ejecutivo. El Dr. Norkunas aporta una experiencia significativa en liderazgo financiero en biotecnología, habiendo ocupado anteriormente el cargo de CFO en Generation Bio (GBIO) y SomaLogic.
Su trayectoria combina experiencia médica como anestesiólogo formado con un amplio conocimiento financiero, incluyendo experiencia en inversión en salud y roles operativos. Este nombramiento se produce en una etapa de importante crecimiento para Tubulis, que está desarrollando candidatos farmacéuticos ADC (Antibody-Drug Conjugate). El Dr. Norkunas se enfocará en avanzar los objetivos estratégicos de la empresa y en posicionarla para el éxito a largo plazo en el espacio ADC.
튜불리스는 매튜 노르쿠나스, MD, MBA를 튜불리스 주식회사의 최고 재무 책임자 및 사장으로 임명했습니다. 회사의 캠브리지 사무소에 본사를 둔 이번 임명은 미국 내 존재감과 경영 리더십을 강화합니다. 노르쿠나스 박사는 제너레이션 바이오 (GBIO)와 소마로직에서 CFO로 재직한 경험이 있는 생명공학 재무 리더십에서 상당한 경험을 가지고 있습니다.
그의 배경은 훈련된 마취의로서의 의학적 전문성과 의료 투자 및 운영 역할에 대한 광범위한 재무 지식이 결합되어 있습니다. 이번 임명은 ADC(항체-약물 접합체) 약물 후보를 개발 중인 튜불리스를 위한 중요한 성장 단계에서 이루어졌습니다. 노르쿠나스 박사는 회사의 전략적 목표를 발전시키고 ADC 분야에서 장기적인 성공을 위해 회사의 포지셔닝에 집중할 것입니다.
Tubulis a nommé Matthew Norkunas, MD, MBA au poste de directeur financier et président de Tubulis Inc. Basé dans le bureau de l'entreprise à Cambridge, cette nomination renforce leur présence aux États-Unis et le leadership exécutif. Le Dr Norkunas apporte une expérience significative en matière de leadership financier dans le secteur biotechnologique, ayant précédemment occupé le poste de CFO chez Generation Bio (GBIO) et SomaLogic.
Son parcours combine une expertise médicale en tant qu'anesthésiste formé avec une grande acuité financière, y compris une expérience dans l'investissement en santé et des postes opérationnels. Cette nomination intervient à un stade de croissance important pour Tubulis, qui développe des candidats médicamenteux ADC (Antibody-Drug Conjugate). Le Dr Norkunas se concentrera sur l'avancement des objectifs stratégiques de l'entreprise et sur son positionnement pour un succès à long terme dans le domaine des ADC.
Tubulis hat Matthew Norkunas, MD, MBA zum Hauptgeschäftsführer und Präsidenten von Tubulis Inc. ernannt. Mit Sitz im Büro des Unternehmens in Cambridge stärkt diese Ernennung ihre Präsenz in den USA und die exekutive Leitung. Dr. Norkunas bringt umfassende Erfahrung in der finanziellen Führung von Biotechnologieunternehmen mit, nachdem er zuvor als CFO bei Generation Bio (GBIO) und SomaLogic tätig war.
Sein Hintergrund verbindet medizinische Expertise als ausgebildeter Anästhesist mit umfangreicher Finanzkompetenz, einschließlich Erfahrungen in der Gesundheitsinvestition und operativen Rollen. Die Ernennung erfolgt in einer wichtigen Wachstumsphase für Tubulis, das ADC (Antibody-Drug Conjugate) Arzneikandidaten entwickelt. Dr. Norkunas wird sich darauf konzentrieren, die strategischen Ziele des Unternehmens voranzubringen und es für langfristigen Erfolg im Bereich ADC zu positionieren.
- Strategic expansion of U.S. presence through Cambridge office
- Appointment of experienced CFO with both medical and financial expertise
- Addition of executive with public company experience (former GBIO CFO)
- None.
“Tubulis has built a strong financial position to advance its portfolio of ADC drug candidates and Matt’s impressive expertise in finance, business operations and capital markets, combined with his deep understanding of value creation in the biotech sector, makes him an outstanding addition to our team,” said Dominik Schumacher, PhD, CEO and Co-founder of Tubulis. “As we focus on the next stage of corporate and pipeline development, his strategic insights and financial acumen will be critical in positioning Tubulis for long-term success.”
“Tubulis is rapidly emerging as a front-runner in the ADC space, with a differentiated approach and cutting-edge technologies designed to overcome long-standing challenges in the field,” said Matthew Norkunas, MD, MBA, CFO of Tubulis. “I am genuinely excited to join the company and look forward to working with the entire Tubulis team to further accelerate its innovative pipeline, which has the potential to make a profound difference in patients’ lives.”
Dr. Norkunas brings extensive experience in financial leadership within the life sciences industry, having served as CFO at publicly listed and private biotech companies. Most recently, he was CFO at Generation Bio (Nasdaq: GBIO), where he oversaw financial operations and strategy for over four years. Before that, he served as CFO and Head of Corporate & Business Development at SomaLogic, driving key corporate growth initiatives. His career also includes experience in healthcare investment and operational roles, providing a broad perspective on biotech financial strategy. In addition to his position at Tubulis, Matthew Norkunas currently serves as a Board Member at oncology-focused cell and gene therapy company Obsidian Therapeutics. He is a trained anesthesiologist with an MD from the University of Maryland School of Medicine and an MBA from the Columbia Business School.
About Tubulis
Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. The two lead programs from our growing pipeline, TUB-040, targeting NaPi2b, and TUB-030, directed against 5T4, are being evaluated in the clinic in high-need solid tumor indications. We will solidify our leadership position by continuing to innovate on all aspects of ADC design leveraging our proprietary platform technologies. Our goal is to expand the therapeutic potential of this drug class for our pipeline, our partners and for patients. Visit www.tubulis.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206915196/en/
For Tubulis
Dominik Schumacher, CEO & Co-founder
Phone: +49 (0) 175 800 5594
Email: contact@tubulis.com
Media Requests for Tubulis
Trophic Communications
Stephanie May, PhD
Phone: +49 (0) 171 185 56 82
Email: tubulis@trophic.eu
Source: Tubulis
FAQ
What is Matthew Norkunas's previous experience before joining Tubulis?
How does the appointment of Matthew Norkunas strengthen Tubulis's market position?
What is Tubulis's current focus in drug development?
What roles will Matthew Norkunas hold at Tubulis?
